Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial

BACKGROUND: This study validated a previously described diffusion MRI phenotype as a potential predictive imaging biomarker in patients with recurrent glioblastoma receiving bevacizumab (BEV). METHODS: A total of 396/596 patients (66%) from the prospective randomized phase II/III EORTC-26101 trial (...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Schell, Marianne, Pflüger, Irada, Brugnara, Gianluca, Isensee, Fabian, Neuberger, Ulf, Foltyn, Martha, Kessler, Tobias, Sahm, Felix, Wick, Antje, Nowosielski, Martha, Heiland, Sabine, Weller, Michael, Platten, Michael, Maier-Hein, Klaus H, Von Deimling, Andreas, Van Den Bent, Martin J, Gorlia, Thierry, Wick, Wolfgang, Bendszus, Martin, Kickingereder, Philipp
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Neuroimaging
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7690360/
https://ncbi.nlm.nih.gov/pubmed/32393964
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa120
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados